Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03914612 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT03914612 · ClinicalTrials.gov record · last posted 2026-07-31

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

StatusActive, Not Recruiting
PhasePhase 3
Started2019-08-22
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This phase III trial studies how well the combination of pembrolizumab, paclitaxel and carboplatin works compared with paclitaxel and carboplatin alone in treating patients with endometrial cancer that is stage III or IV, or has come back after a period of improvement (recurrent). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Paclitaxel and carboplatin are chemotherapy drugs used as part of the usual treatment approach for this type of cancer. This study aims to assess if adding immunotherapy to these drugs is better or worse than the usual approach for treatment of this cancer.

Amendment record 473 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 473 times since 2019-04-12; most recent amendment 2026-07-01. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2022-12-07
Status change Recruiting→Active, Not Recruitingv421
2020-12-22
Status change Suspended→Recruitingv106
2020-04-07
Status change Recruiting→Suspendedv78
2019-08-16
Status change Not Yet Recruiting→Recruitingv4
Trial Details
NCT Number NCT03914612
Lead Sponsor National Cancer Institute (NCI)
Collaborators: Canadian Cancer Trials Group, NRG Oncology
Conditions Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Recurrent Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma +8 more
Enrollment 813 participants
Start Date 2019-08-22
Primary Completion 2022-12-16 (estimated)
Study Completion 2026-09-26 (estimated)
Updated on ClinicalTrials.gov 2026-07-31